Sleep Disordered Breathing (SDB) Prevalence and Cardiovascular Outcomes of Myocardial Infarction (MI) Survivors

The AMISLEEP study is nested in the "FRENCHIE" registry. The objective is to use routine clinical and polygraphic data to capture SDB/SAS (Sleep Disordered Breathing/Sleep Apnea Syndrome) physiological heterogeneity in relation to clinically relevant cardiovascular outcomes. Specifically, the investigators hypothesize that unique clusters (phenotypes) of patients could be identified by applying unsupervised learning methods to these data and that the clusters would be differentially associated with risk of adverse cardiovascular outcomes (ACS), TIA, stroke or death). The ultimate goal is to identify patients more at risk that could be included in interventional studies that would test whether SDB/SAS treatment can improve this risk.

Inclusion Criteria: * Patient included in FRENCHIE registry (cf. NCT04050956 for FRENCHIE registry's selection criteria) * Signed consent for AMI-Sleep study Exclusion Criteria: * Patient under treatment for SDB/SAS prior to its inclusion in FRENCHIE registry * Cognitive disorientation and communicative disabilities (left to investigator's discretion) not able to fill-out a questionnaire * Severe diseases with anticipated mortality less than 6 months